A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development

Drug Metabolism Reviews

Volumn 32, Issue 2, 2000, Pages 219-240

  Cross, D M ^a   Bayliss, M K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cell culture; Cryopreservation; Drug metabolism; Enzyme kinetics; Extraction ratio; Hepatic clearance; Hepatocytes; Intrinsic clearance; Liver slices; Loxtidine; Ranitidine

Indexed keywords

BROMSULFOPHTHALEIN; CYCLOSPORIN A; ETHOXYCOUMARIN; LIDOCAINE; LOXTIDINE; OMEPRAZOLE; PENTOBARBITAL; RANITIDINE; RIFAMPICIN; TACROLIMUS; TESTOSTERONE; THIAMAZOLE;

ARTICLE; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SULFATION; DRUG TRANSFORMATION; LIVER CELL; LIVER CLEARANCE;

ANIMALS; CELLS, CULTURED; DRUG DESIGN; HUMANS; LIVER; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS;

EID: 0034111854     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100100574     Document Type: Article

References (94)

1. A. Parkinson, Biotransformation of xenobiotics, in Casarette and Doull's Toxicology, The Basic Science of Poisons, 5th ed. (C. D. Klassen, ed.), McGraw-Hill, New York, 1996, pp. 113-186.
2. H. Denk, Human surgical and postmortem material. Ethically justifiable? in Scientific Alternatives to Animal Experiments (F. Lembeck, ed.), Ellis Horwood, Chichester, 1989, pp. 75-79.
3. M. K. Bayliss and P. Skett, Isolation and culture of human hepatocytes, in Human Cell Culture Protocols (G. E. Jones, ed.), Humana Press, Totowa, NJ, 1996, pp. 369-389.
4. M. N. Berry, A. M. Edwards, and G. J. Barritt, in Isolated Hepatocyte Preparation; Properties and Applications (R. H. Burdon and P. H. van Knippenberg, eds.), Laboratory Techniques in Biochemistry and Molecular Biology Vol. 21. Elsevier, Amsterdam, 1991, pp. 1-460.
5. K. Lavrijsen, J. van Houdt, D. van Dyck, J. Hendrickx, M. Bockx, W. Hurkmans, W. Meuldermans, L. Le Jeune, W. Lauwers, and J. Heykants, Comparative metabolism of flunarizine in rats, dogs and man: An in vitro study with subcellular liver fractions and isolated hepatocytes, Xenobiotica, 22(7), 815-836 (1992).
6. G. W. Sandker, R. M. E. Vos, P. C. Delbressine, M. J. H. Slooff, D. K. F. Meijer, and G. M. M. Groothuis, Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: Analysis of interspecies variability and comparison with metabolism in vivo, Xenobiotica, 24(2), 143-155 (1994).
7. R. Rahmani, G. de Sousa, F. Marre, F. Nicolas, and M. Placidi, Potential of freshly isolated and cryopreserved human hepatocytes in drug research and development, in Human Cells in In Vitro Pharmaco-toxicology (V. Rogiers, W. Sonck, E. Shephard, and A. Vercruysse, eds.), Vub Press, Brussels, 1993, pp. 117-138.
8. S. A. Pahernik, J. Schmid, T. Sauter, F. W. Schildberg, and H.-G. Koebe, Metabolism of pimobendan in long-term human hepatocyte culture: In vivo-in vitro comparison, Xenobiotica, 25(8), 811-823 (1995).
9. G. de Souza, N. Florence, B. Vallès, P. Coassolo, and R. Rahmani, Relationships between in vitro and in vivo biotransformation of drugs in humans and animals: Pharmaco-toxicological consequences, Cell Biol. Toxicol., 11, 147-153 (1995).
10. P. Maurel, The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man, Adv. Drug Deliv. Rev., 22, 105-132 (1996).
11. M. K. Bayliss, J. A. Bell, W. N. Jenner, G. R. Park, and K. Wilson. Utility of hepatocytes to model species differences in metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man, Xenobiotica, 29(3), 253-268 (1999).
12. M. Humpel, D. Sostarek, H. Gieschen, and C. Labitzky, Studies on the biotransformation of ionazolac, bromerguride, lisuride and terguride in laboratory animals and their hepatocytes, Xenobiotica, 19, 361-377 (1989).
13. R. J. Chenery, A. Ayrton, H. G. Oldham, P. Standring, S. J. Norman, T. Seddon, and R. Kirby, Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig and man, Drug Metab. Dispos., 15, 312-317 (1987).
14. T. Lave, S. Dupin, M. Schmitt, M. Kapps, J. Meyer, B. Morgenroth, R. C. Chou, D. Jaeck, and P. Coassolo, Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase. Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans, Xenobiotica, 26, 839-851 (1996).
15. T. Lave, P. Coassolo, G. Ubeaud, B. B. R. Brandt, C. Schmitt, S. Dupin, D. Jaeck, and R. C. Chou. Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling, Pharmaceut. Res., 13, 97-101 (1996).
16. D. M. Cross, A consideration of the enzymology underlying ranitidine metabolism and drug interations, J. Biopharmaceut. Sci., 2(4), 339-377 (1991).
17. P. Ammann and P. Maier, Preservation and inducibility of xenobiotic metabolism in long-term cultures of adult rat liver cell aggregates, Toxicol. In Vitro, 11, 43-56 (1997).
18. D. Diaz, I. Fabre, M. Daujat, B. Saint-Aubert, P. Borries, H. Michel, and P. Maurel, Omeprazole is an aryl hydrocarbon like inducer of human hepatic cytochrome P450, Gastroenterology, 99, 737-747 (1990).
19. A. Kern, A. Bader, R. Pichmayr, and K. F. Sewing, Drug metabolism in hepatocyte sandwich cultures of rats and humans, Biochem. Pharmacol., 54, 761-772 (1997).
20. J-B. Ferrini, L. Pichard, J. Domergue, and P. Maurel, Long-term primary cultures of adult human hepatocytes, Chem.-Biol. Interact., 107, 31-45 (1997).
21. L. Pichard, I. Fabre, G. Fabre, J. Domergue, B. S. Aubert, G. Mourad, and P. Maurel, Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P450 (Cyclosporin A Oxidase) in primary cultures of human hepatocytes and in liver microsomes, Drug Metab. Dispos., 18(5), 595-606 (1990).
22. P. Skett, Problems in using isolated and cultured hepatocytes for xenobiotic metabolism/metabolism-based toxicity testing - solutions? Toxicol. In Vitro, 8(3), 491-504 (1994).
23. A. Guillouzo, F. Morel, D. Ratanasavanh, C. Chesne, and C. Guguen-Guillouzo, Long-term cultures of functional hepatocytes, Toxicol. In Vitro, 4(5/4), 415-427 (1990).
24. H-G, Koebe, S. Pahernik, P. Eyer, and F-W. Schildberg, Collagen gel immobilisation: A useful cell culture technique for long-term metabolic studies on human hepatocytes, Xenobiotica, 24(2), 95-107 (1994).
25. L. Liu, E. L. LeCluyse, J. Liu, and C. D. Klaassen, Sulfotransferase gene expression in primary cultures of rat hepatocytes, Biochem. Pharmacol., 52, 1621-1630 (1996).
26. A. Guillouzo, J-M. Begue, J-P. Campion, M-N. Gascoin, and C. Guguen-Guillouzo, Human hepatocyte cultures: a model of pharmaco-toxicological studies, Xenobiotica, 15(8/9), 635-641 (1985).
27. A. Guillouzo, J-M. Begue, G. Maurer, and P. Koch, Identification of metabolic pathways of pindolol and fluperlapine in adult human hepatocyte cultures, Xenobiotica, 18, 131-139 (1988).
28. M. T. Donato, J. V. Castell, and M. J. Gónnez-Lechón, Co-cultures of hepatocytes with epithelial-like cell lines: Expression of drug biotransformation activities by hepatocytes. Cell Biol. Toxicol., 7(1), 1-14 (1991).
29. J. S. Sidhu, F. M. Farin, and C. J. Omiecinski, Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2 and 3A1 genes in primary adult rat hepatocyte culture, Arch. Biochem. Biophys., 301(1), 103-113 (1993).
30. E. L. LeCluyse, K. L. Audus, and J. H. Hochman, Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration, Am. J. Physiol., 266 (Cell Physiol. 35), C1764-C1774 (1994).
31. F. Oesch and B. Diener, Cell systems for use in studies on the relationship between foreign compound metabolism and toxicity, Pharmacol. Toxicol., 76, 325-327 (1995).
32. V. Rogiers, Cultures of human hepatocytes in in vitro pharmaco-toxicology, in Human Cells in In Vitro Pharmaco-toxicology (V. Rogiers, W. Sonck, E. Shephard, and A. Vercruysse, eds.), Vub Press, Brussels, 1993, pp. 77-115.
33. A. Guillouzo, F. Morel, O. Fardel, and B. Meunier, Use of human hepatocyte cultures for drug metabolism studies, Toxicology, 82, 209-219 (1993).
34. V. Rogiers and A. Vercruysse, Rat hepatocyte cultures and co-cultures in biotransformation studies of xenobiotics, Toxicology, 82, 193-208 (1993).
35. Y. Kono, S. Yang, and E. Roberts, Extended primary culture of human hepatocytes in a collagen gel sandwich system, In Vitro Cell Dev. Biol.-Animal, 33, 467-472 (1997).
36. C. Guyomard, L. Rialland, B. Fremond, C. Chesne, and A. Guillouzo, Influence of alginate gel entrapment and cryopreservation on survival and xenobiotic metabolism capacity of rat hepatocytes, Toxicol. Appl. Pharmacol., 141(2), 349-356 (1996).
37. C. Selden, E. Roberts, G. Stamp, K. Parker, P. Winlove, T. Ryder, H. Platt, and H. Hodgson, Comparison of three solid phase supports for promoting three-dimensional growth and function of human liver cell lines, Artif. Organs, 22(4), 308-319 (1998).
38. R. A. Roberts and A. R. Soames, Hepatocyte spheroids: Prolonged hepatocyte viability for in vitro modeling of nongenotoxic carcinogenesis, Fundam. Appl. Toxicol., 21, 149-158 (1993).
39. J. Z. Tong, P. DeLagausie, V. Furlan, T. Cresteil, O. Bernard, and F. Alvarez, Long-term culture of adult rat hepatocyte spheroids, Exp. Cell Res., 200, 326-332 (1992).
40. Z. Abdel-Razzak, P. Loyer, A. Fautrel, J. C. Gautier, L. Corcos, B. Turlin, P. Beaune, and A. Guillouzo, Cytokines down-regulate expression of major cytochrome P450 enzymes in adult human hepatocytes in primary culture, Mol. Pharmacol., 44, 770-775 (1993).
41. A. Bader, K. Zech, O. Crome, U. Christians, B. Ringe, R. Pichlmayr, and K.-F. R. Sewing, Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals, Xenobiotica, 24(7), 623-633 (1994).
42. A. Rotem, H. W. T. Matthew, P. H. Hsiao, M. Toner, R. G. Tompkins, and M. L. Yarmush, The activity of cytochrome P450IA1 in stable cultured rat hepatocytes. Toxicol. In Vitro, 9(2), 139-149 (1995).
43. A. Bader, E. Knop, A. Kern, K. Böker, N. Frühauf, O. Crome, H. Esselmann, C. Pape, G. Kempka, and K.-F. R. Sewing, 3-D coculture of hepatic sinusoidal cells with primary hepatocytes - design of an organotypical model, Exp. Cell Res., 226, 223-233 (1996).
44. S. Surapaneni, T. Pryor, M. Klein, and H. W. T. Matthew, Rapid hepatocyte spheroid formation: Optimization and long term function in perfused microcapsules, ASAIO J., 43(5), 848-853 (1997).
45. H. Takabatake, N. Koide, and T. Tsuji, Encapsulated multicellular spheroids of rat hepatocytes produce albumin and urea in a spouted bed circulating system, Artif. Organs, 15(6), 474-480 (1991).
46. H. O. Jauregui, S. Naik, H. Santangini, J. Pan, D. Trenkler, and C. Mullon, Primary cultures of rat hepatocytes in hollow fiber chambers, In Vitro Cell Dev. Biol., 30A, 23-29 (1994).
47. M. L. Rose, I. Rusyn, H. K. Bojes, D. R. Germolec, M. Luster, and R. G. Thurman, Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation, Drug Metab. Rev., 31(1), 87-99 (1999).
48. P. D. Worboys, A. Bradbury, and J. B. Houston, Kinetics of drug metabolism in rat liver slices, Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high-and low-clearance compounds, Drug Metab. Dispos., 23(3), 393-397 (1995).
49. P. D. Worboys, A. Bradbury, and J. B. Houston, Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes, Drug Metab. Dispos., 24(6), 676-681 (1996).
50. P. D. Worboys, B. Brennan, A. Bradbury, and J. B. Houston, Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition, Xenobiotica, 26(9), 897-907 (1996).
51. P. D. Worboys, A. Bradbury, and J. B. Houston, Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate, Drug Metab. Dispos., 25(4), 460-467 (1997).
52. J. A. Beamand, R. J. Price, J. C. Phillips, W. H. Butler, G. D. Glynne Jones, T. G. Osimitz, K. L. Gabriel, F. J. Preiss, and B. G. Lake, Lack of effect of piperonyl butoxide on unscheduled DNA synthesis in precision-cut human liver slices, Mutat. Res., 371(3-4), 273-282 (1996).
53. A. T. Drahushuk, B. P. McGarrigle, H. L. Tai, S. Kitareewan, J. A. Goldstein, and J. R. Olson, Validation of precision-cut liver slices in dynamic organ culture as an in vitro model for studying CYP1A1 and CYP1A2 induction, Toxicol. Appl. Pharmacol., 140(2), 393-403 (1996).
54. M. C. Wright and A. J. Paine, Evidence that the loss of rat liver cytochrome P450 in vitro is not solely associated with the use of collagenase, the loss of cell-cell contacts and/or the absence of an extracellular matrix, Biochem. Pharmacol., 43(2), 237-243 (1992).
55. G. Powis, K. S. Santone, D. C. Melder, L. Thomas, D. J. Moore, and T. J. Wilke, Cryopreservation of rat and dog hepatocytes for studies of xenobiotic metabolism and activation, Drug Metab. Dispos., 15(6), 826-832 (1987).
56. L. J. Loretz, A. P. Li, M. W. Flye, and A. G. E. Wilson, Optimization of cryopreservation procedures for rat and human hepatocytes, Xenobiotica, 19(5), 489-498 (1989).
57. J. A. Coundouris, M. H. Grant, J. Engeset, J. C. Petrie, and G. M. Hawksworth. Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity studies, Xenobiotica, 23(12), 1399-1409 (1993).
58. J. M. Pang, J. Zaleski, and F. C. Kauffman, Toxicity of allyl alcohol in primary cultures of freshly isolated and cryopreserved hepatocytes maintained on hydrated collagen gels, Toxicol. Appl. Pharmacol., 142, 87-94 (1997).
59. D. M. Ziegler, Microsomal flavin-containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds, in Enzymatic Basis of Detoxication 1 (W. B. Jakoby, ed.), Academic Press, New York, 1980, pp. 201-227.
60. D. M. Ziegler, Flavin-containing monooxygenases: Catalytic mechanism and substrate specificities, Drug Metab. Rev., 19(1), 1-32 (1988).
61. R. A. Prough and D. M. Ziegler, The relative participation of liver microsomal amine oxidase and cytochrome P450 in N-demethylation reactions, Arch. Biochem. Biophys., 180, 363-373 (1977).
62. G. L. Kedderis and D. E. Rickert, Inhibition of the microsomal N-hydroxylation of 2-amino-6-nitrotoluene by a metabolite of methimazole, Biochem. Biophys. Res. Commun., 113(2), 433-438 (1983).
63. Z. Guo, S. Raeissi, R. B. White, and J. C. Stevens, Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes, Drug Metab. Dispos., 25(3), 390-393 (1997).
64. S. P. James, The biochemistry of endogenous organosulphur compounds, Drug Metab. Drug Interact., 6(3-4), 167-182 (1988).
65. J. B. Watkins and C. D. Klaassen, Chemically-induced alteration of UDP-glucuronic acid concentration in rat liver, Drug Metab. Dispos., 11, 37-40 (1983).
66. T. Mizuma, M. Machida, M. Hayashi, and S. Awazu, Correlation of drug conjugative metabolism rates between in vivo and in vitro: Glucuronidation and sulphation of p-nitrophenol as a model compound, J. Pharmacobiodyn., 5, 811-817 (1982).
67. L. R. Schwarz, Modulation of sulphation and glucuronidation of 1-naphthol in isolated rat liver cells, Arch. Toxicol., 44, 137-145 (1980).
68. E. Oddy, M. Manchee, and M. W. H. Coughtrie, Assessment of rat liver slices as a suitable model system for studying the simultaneous sulphation and glucuronidation of phenolic xenobiotics, Xenobiotica, 27(4), 369-377 (1997).
69. K. Singh, S. L. Tripp, A. W. Dunton, F. L. Douglas, and A. Rakhit, Determination of in vivo hepatic extraction ratio from in vitro metabolism by rat hepatocytes, Drug Metab. Dispos., 19, 990-995 (1991).
70. E. L. Ashforth, D. J. Carlile, R. J. Chenery, and J. B. Houston, Prediction of in vivo disposition from in vitro systems: Clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data, J. Pharmacol. Exp. Therapeut., 274, 761-766 (1995).
71. K. A. Hayes, B. Brennan, R. J. Chenery, and J. B. Houston, In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data, Drug Metab. Dispos., 23, 349-353 (1995).
72. K. Zomorodi, D. J. Carlile, and J. B. Houston, Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance, Xenobiotica, 25, 907-916 (1995).
73. T. Lave, A. H. Schmitt-Hoffman, P. Coassolo, B. Valles, G. Ubeaud, B. B. R. Brandt, and R. C. Chou, A new extrapolation method from animals to man: Application to a metabolised compound, mofarotene, Life Sci., 56, 473-478 (1995).
74. D. J. Carlile, K. Zomorodi, and J. B. Houston, Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes and intact liver, Drug Metab. Dispos., 25, 903-911 (1997).
75. T. Lave, S. Dupin, C. Schmitt, B. Valles, G. Ubeaud, R. Chou, D. Jaeck, and P. Coassolo, The use of hepatocytes to select compounds based on their expected extraction ratios in humans, Pharmaceut. Res., 14, 152-155 (1997).
76. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, and Y. Sugiyama, Prediction of in vivo metabolism in the human liver from in vitro metabolism data, Pharmacol. Therapeut., 73, 147-171 (1997).
77. H. Boxenbaum and C. di Lea, First-time in human dose selection: Allometric thoughts and perspectives, J. Clin. Pharmacol., 35, 957-966 (1995).
78. G. Ubeaud, C. Schmitt, D. Jaeck, T. Lave, and Ph. Coassolo, Bosentan, a new endothelin receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data, Xenobiotica, 25(12), 1381-1390 (1995).
79. J. B. Houston and D. J. Carlile, Incorporation of in vitro drug metabolism data into physiologically based pharmacokinetic models, Toxicol. In Vitro, 11, 473-478 (1997).
80. J. B. Houston, Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics, Toxicol. In Vitro, 8(4), 507-512 (1994).
81. J. B. Houston, Commentary. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance, Biochem. Pharmacol., 47, 1469-1479 (1994).
82. A. E. M. Vickers, S. Connors, M. Zollinger, W. A. Biggi, A. Larrauri, J. P. W. Vogelaar, and K. Brendel, The biotransformation of the ergot derivative CQA 206-291 in human, dog, and rat liver slice cultures and prediction of in vivo plasma clearance, Drug Metabol. Dispos., 21(3), 454-459 (1993).
83. H. G. Oldham, R. J. Chenery, P. Standring, S. J. Norman, A. Garton, and A. D. Ayrton, Drug metabolism kinetic studies in a hepatocyte model, Food Chem. Toxicol., 24, 761-762 (1986).
84. K. S. Pang, P. Kong, J. A. Terrell, and R. E. Billings, Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes, Drug Metabol. Dispos., 13, 42-50 (1985).
85. E. Bodd, C. A. Drevon, N. Kveseth, H. Olsen, and J. Morland, Ethanol inhibition of codeine and morphine metabolism in isolated rat hepatocytes, J. Exp. Therapeut., 237, 260-264 (1986).
86. I. M. Arias, Introduction, in The Liver: Biology and Pathobiology (I. M. Arias, W. B. Jakoby, H. Popper, D. Scahacter, and D. A. Shafritz, eds.), Raven Press, New York, 1988, pp. 3-10.
87. D. J. Morgan and R. A. Smallwood, Clinical significance of pharmacokinetics: Models of hepatic elimination, Clin. Pharmacokinet., 18, 61-76 (1990).
88. S. Ekins, J. A. Williams, G. I. Murray, M. D. Burke, N. C. Marchant, J. Engeset, and G. M. Hawkesworth, Xenobiotic metabolism in rat, dog and human precision-cut liver slices, freshly isolated hepatocytes and vitrified precision-cut liver slices, Drug Metab. Dispos., 24, 990-995 (1996).
89. K. Ito, T. Iwatsubo, S. Kanamitsu, N. Nakajima, and Y. Sugiyama, Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport, Ann. Rev. Pharmacol. Toxicol., 38, 461-499 (1998).
90. I. Mahmood and J. D. Balian, The pharmacokinetics principles behind scaling from preclinical results to Phase 1 protocols, Clin. Pharmacokinet., 36(1), 1-11 (1999).
91. H. Boxenbaum, Interspecies variation in liver weight, hepatic blood flow and antipyrene clearance: Extrapolation of data to benzodiazepines and phenytoin, J. Pharmacokinet. Biopharmaceut., 8, 165-176 (1980).
92. A. Varughese and C-S. C. Lee, Disposition kinetics of ranitidine in rats, Drugs Exp. Clin. Res., 9(11), 837-842 (1983).
93. P. J. Eddershaw, A. P. Chadwick, D. M. Higton, S. H. Fenwick, P. Linacre, W. N. Jenner, J. A. Bell, and G. R. Manchee, Absorption and disposition of ranitidine hydrochloride in rat and dog, Xenobiotica, 26(9), 947-956 (1996).
94. 2-receptor antagonists, in Sulphur-Containing Drugs and Related Organic Compounds (L. A. Damani, ed.), Ellis Horwood, Chichester, 1989, Vol 3, Part A, pp. 53-86.